The University of Oxford has resumed its clinical trials of Covid-19 vaccine after being paused for several days due to the illness of one of the volunteers participating in the experiments.
The decision to resume the trials came after a trial review was conducted by an independent committee and the British Medicines and Healthcare products Regulatory Agency, Oxford University announced.
AstraZeneca pharmaceutical company, which is developing the vaccine in cooperation with the university, announced that the trials have been temporarily stopped to investigate whether the reported side effect is related to the vaccine.
The Oxford University vaccine is among the most promising vaccines that the world expects to reach the stage of manufacturing in an effort to reduce infection with the Coronavirus.
The vaccine will be available by the end of this year or early next year,AstraZeneca hopes.
The potential AstraZeneca vaccine is one of nine around the world currently in late-stage Phase 3 trials.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
WHO urges collaboration on the origin of coronavirus
New Covid variant ‘probable’ this year
Russian WWII veteran beats Covid-19
Europe boosts defences, pushes vaccination
Macron changes phone over spyware
Norway marks decade since Breivik massacre
‘Pingdemic’ puts Britain’s food supply under strain
French protest against Covid-19 health pass
UK demands EU agreement on new North Ireland deal